Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting

27 Jan 2014 14:00

RNS Number : 5936Y
ViaLogy PLC
27 January 2014
 



ViaLogy plc ("ViaLogy" or "the Company")

 

Result of General Meeting

 

ViaLogy is pleased to announce that at a General Meeting of the Company held earlier today, all resolutions were duly passed.

 

Further to the announcements of 7 January 2014 and 24 January 2014, ViaLogy has raised, via a Placing of 1,100,000,000 Ordinary Shares at 0.1p per share, £1.1 million (before expenses), and an additional £519,820 via an oversubscribed Open Offer to existing shareholders through the issue of 519,820,122 Ordinary Shares at 0.1p per share.

 

The Open Offer and Placing have therefore raised a total of £1,619,820 (before expenses). Application has been made for the admission of 1,649,820,122* Ordinary Shares of 0.1p each (following the Capital Reorganisation) to trading on AIM ("Admission") and dealings are expected to commence in these new shares on Tuesday 28 January 2014.

 

Following Admission, the Company shall have 2,689,460,366 ordinary shares of 0.1p in issue, which figure may be used after Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

 

Following their participation in the Placing and Open Offer, the following Directors of ViaLogy have an interest in the Ordinary Share Capital of the Company as follows:

 

Director

Current Holding

Placing Participation

Open Offer Entitlement

Total Holding

% Holding

Adam Reynolds

Nil

75,000,000

Nil

75,000,000

2.79

Dr. Robert Dean

2,897,304

Nil

1,448,652

4,345,956

0.17

Dr. Sandeep Gulati

6,904,412

Nil

3,912,184

10,816,596

0.41

Nicholas Mustoe

Nil

150,000,000

Nil

150,000,000

5.58

 

Capitalised terms used in this announcement are as defined in the shareholder circular dated 7 January 2014.

 

*includes 30,000,000 ordinary shares of 0.1peach being issued as part consideration for fees relating to Corporate Finance advice

 

For further information:

 

ViaLogy PLC

Mark Collingbourne mark.collingbourne@vialogy.com

 

Nominated Advisor to ViaLogy PLC (Cantor Fitzgerald Europe)

Mark Percy / Catherine Leftley - Corporate Finance +44 (0) 207 894 7000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ROMBXGDBUSDBGSR
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.